Publication
FOLFOX4 Plus Cetuximab for Patients With Previously Untreated Metastatic Colorectal Cancer According to Tumor RAS and BRAF Mutation Status: Updated Analysis of the CECOG/CORE 1.2.002 Study.
Authors not recorded
- Source
- PubMed
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CIVIC-20260908-000001
Abstract
Abstract (excerpt)
Only the opening of the abstract is shown; abstract text may carry publisher copyright.
Data not yet available
Linked entities
Linked entities (11)
How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.
Validated 11
- cancerMalignant Colorectal Neoplasmcivic_curation1.00
- drugCetuximabcivic_curation1.00
- drugFOLFOX-4 Regimencivic_curation1.00
- geneBRAFcivic_curation1.00
- geneKRAScivic_curation1.00
- geneNRAScivic_curation1.00
- variantBRAF V600Ecivic_curation1.00
- variantKRAS A146Tcivic_curation1.00
- variantKRAS G13Dcivic_curation1.00
- variantNRAS G12Dcivic_curation1.00
- variantNRAS Q179*civic_curation1.00
Curated evidence
Evidence citing this paper (5)
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 25666295
- Run
- ING-CIVIC-20260908-000001
| Therapy | Cancer | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| BRAF V600E1 | ||||||||
| Cetuximab + FOLFOX-4 RegimenCombination | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | 4 | accepted | EID3739In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with BRAF V600E and wildtype NRAS/KRAS (n=14) mutation treated with FOLFOX4 plus cetuximab were associat… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC | civic |
| KRAS A146T1 | ||||||||
| Cetuximab + FOLFOX-4 RegimenCombination | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | 3 | accepted | EID3858In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations and wildtype BRAF (n=10), including A146T (N=3), G15D (N=1), and V152M/NRAS V160A, tr… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC | civic |
| KRAS G13D1 | ||||||||
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | — | accepted | EID3882In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC | civic |
| NRAS G12D1 | ||||||||
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | — | accepted | EID3693In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC | civic |
| NRAS Q179*1 | ||||||||
| Cetuximab | Malignant Colorectal NeoplasmCURATED_BROADER | Predictive | B | Supports Resistance | — | accepted | EID4785In a retrospective study of 148 treatment naive metastatic colorectal cancer patients, patients with RAS mutations (n=10), including KRAS A146T, KRAS G13D, NRAS G12D and NRAS Q179*, treated with FOLFO… (full text at CIViC) PMID 25666295 · Kaczirek et al., 2015 · Open in CIViC | civic |